Olmesartan medoxomil-induced angioedema

Annals of Pharmacotherapy

Volumn 41, Issue 3, 2007, Pages 518-520

  Nykamp, Diane ^a,b   Winter, Erin E ^a  

^a MERCER UNIVERSITY   (United States)

^b Saint Joseph's Hospital of Atlanta   (United States)

Author keywords

Angioedema; Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Olmesartan medoxomil

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESCITALOPRAM; OLMESARTAN;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CASE REPORT; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FACE EDEMA; FEMALE; HUMAN; HYPERTENSION; PRIORITY JOURNAL; SWELLING; SYMPTOM;

ANGIONEUROTIC EDEMA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; DILTIAZEM; FACE; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MIDDLE AGED; NECK; TETRAZOLES;

EID: 34047237041     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H566     Document Type: Article

References (26)

1. Nussberger J, Koike H. Antagonizing the angiotensin II subtype I receptor: a focus on olmesartan medoxomil. Clin Ther 2004;26:A12-20.
2. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002;62:1345-53.
3. Howes LG, Tran D. Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema? Drug Saf 2002;25:73-6.
4. Abdi R, Dong VM, Lee CJ, et al. Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. Pharmacotherapy 2002;22:1173-5.
5. Cicardi M, Zingale LC, Bergamaschini L, et al. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med 2004;164:910-3.
6. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2003;360:752-60.
7. Sander GE, McKinnie JJ, Greenberg SS, et al. Angiotensin-converting inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction. Prog Cardiovasc Dis 1999;41:265-300.
8. Bouzehrhane F, Thibault G. Is angiotensin II a proliferative factor of cardiac fibroblasts? Cardiovasc Res 2002;53:304-12.
9. Irons BK, Kumar A. Valsartan-induced angioedema. Ann Pharmacother 2003;37:1024-7. DOI 10.1345/aph.1C520
10. Kaplan A, Greaves MW. Angioedema. J Am Acad Dermatol 2005;53: 373-88.
11. Chiu A, Krowiak E, Deeb Z. Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology. Laryngoscope 2001;111:1729-31.
12. Dykewicz MS. Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management. Curr Opin Allergy Clin Immunol 2004;4:267-70.
13. Campbell DJ, Krum H, Esler MD. Losartan increases bradykinin levels in hypertensive humans. Circulation 2005;111:315-20.
14. Lo K. Angioedema associated with candesartan. Pharmacotherapy 2002; 22:1176-9. DOI 10.1345/aph
15. Nielsen EW. Hypertensive shock and angioedema from angiotensin II receptor blocker: a class effect in spite of tripled tryptase values. J Intern Med 2005;258:3875-7.
16. Borazan A, Ustun H, Yilmaz A. Angioedema induced by angiotensin II blocker telmisartan. Allergy 2003;58:454.
17. Package insert. Teveten (eprosartan mesylate). Bridgewater, NJ: Biovail Pharmaceuticals Inc., January 2004.
18. Package insert. Benicar (olmesartan medoxomil). Parsippany, NJ: Sankyo Pharma Inc., July 2005.
19. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet 2003;362:772-6.
20. Warner KK, Visconti JA, Tschampel MM. Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema. Ann Pharmacother 2000;34:526-8. DOI 10.1345/aph.l9294
21. Griendling KK, Lassegue B, Alexander RW. Angiotensin receptors and their therapeutic implications. Annu Rev Pharmacol Toxicol 1996;36: 281-306.
22. Volpe M, De Paolis P. Angiotensin II AT2 subtype receptors: an emerging target for cardiovascular therapy. Ital Heart J 2000;1:96-103.
23. Gold Standard. Clinical Pharmacology, Olmesartan mechanism of action. September 2006. www.clincalpharmacology.com/Default.asp (accessed 2007 Mar 2).
24. Molinaro G, Cugno M, Perz M, et al. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9) bradykinin. J Pharmacol Exp Ther 2002;303:232-7.
25. Hasler C, Nussberger J, Maillard M, Forclaz A, Brunner HR, Burnier M. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther 2005;78:501-7.
26. Naranjo CA, Busto O, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.